尚太科技(001301.SZ):預計2024年4C及以上快充產品將在公司對外銷售中佔據優勢地位
格隆匯3月18日丨尚太科技(001301.SZ)披露投資者關係活動記錄表顯示,公司在2023年已完成4C及以上產品的開發和導入,2024年一季度以來迎來大規模出貨,隨着終端新一代新能源汽車的銷售保持火熱態勢,公司相應快充產品出貨量將持續增加,佔比相應提升,預計2024年4C及以上快充產品將在公司對外銷售中佔據優勢地位。
2023年以來,伴隨市場需求變化和技術進步,公司產品結構發生了積極的變化,主流產品在容量、倍率、循環等均實現了較大幅度提升,適應新一代動力電池和儲能電池的需要,而新產品的推出,也帶動了公司銷售量的增長和市場份額的上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.